Patient dies in Bristol Myers Squibb CAR-T autoimmune disease trial

A patient enrolled in a Bristol Myers Squibb clinical trial investigating CAR-T cell therapy for autoimmune diseases has died, according to reporting by STAT News. The death adds to a growing body of safety data being accumulated as CAR-T approaches — which engineer a patient's own immune cells to attack specific targets — are extended from haematological cancers, where they are established, into autoimmune conditions such as lupus and myositis.

CAR-T therapies carry well-characterised risks including cytokine release syndrome and neurotoxicity. Whether those risk profiles remain acceptable when the underlying condition is not itself immediately life-threatening is a question researchers and regulators are actively working through. The STAT News report notes that no consensus safety bar yet exists for autoimmune CAR-T trials, and that the field is grappling with how to weigh early signals against potential long-term benefit.

The BMS trial in question has not been publicly identified beyond the STAT report, which is behind a paywall. Details of the patient, cause of death, and the specific autoimmune indication are not available from the public lede alone. Researchers and clinicians following this area should consult the primary STAT News article and any subsequent regulatory communications for specifics.